A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs MVA-p53 (Primary) ; Gemcitabine
- Indications Ovarian cancer
- Focus Adverse reactions
- 18 Aug 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated
- 11 Jan 2017 Status changed from recruiting to active, no longer recruiting.